← All peptidesBlends
CJC-1295 (with DAC) + Ipamorelin
CJC-1295 (with DAC) + Ipamorelin
Longer-acting GHRH-analog variant paired with Ipamorelin, researched for sustained baseline GH elevation with fewer injections.
Typical dose
100–300 mcg
Frequency
1-2x weekly (CJC) + Ipamorelin as scheduled
Half-life
—
Route
subcutaneous
Typical vial sizes
4 mg10 mg
Sample reconstitution
4 mg vial · 2 mL bac water · 200 mcg dose
- Draw volume
- 0.100 mL
- Insulin units
- 10 units
- Concentration
- 2.00 mg/mL
- Doses per vial
- 20.0
Research notes
As sold: CJC-1295 DAC 2mg + Ipamorelin 2mg (also 5mg+5mg). DAC's ~6-8 day half-life allows less frequent dosing.
Further reading
- Published research on CJC-1295 (with DAC) + Ipamorelin (PubMed) →
- Clinical trials for CJC-1295 (with DAC) + Ipamorelin (ClinicalTrials.gov) →
Links open live searches on authoritative databases — verify dosing and safety against primary sources.
Research use only.
Information on this page is a reference log compiled from public sources and is not medical advice. Consult a licensed physician before making any decisions about your health.